Physician profile
Marc Lashley
NPI 1922040070
$3,790.76
in general payments reported to CMS, 2019-2025
29 companies · $621 in 2025
The $621 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $514 · 2021: $612 · 2022: $530 · 2023: $447 · 2024: $499 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $950.18 | 2019-2025 | Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $452.36 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Sanofi Pasteur INC. | $286.85 | 2020-2024 | |
| Pfizer INC. | $280.39 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.90 | 2020-2022 | |
| Kaleo, INC. | $172.03 | 2020-2023 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $167.92 | 2019-2024 | |
| Corium, LLC | $151.74 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $125.51 | 2020-2025 | Doc Band |
| Alk-Abello, INC | $109.73 | 2023-2025 | Neffy, Odactra, Grastek |
| Tris Pharma INC | $84.70 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $83.19 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $76.68 | 2024-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Sobi, INC | $75.91 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $65.44 | 2025 | Daybue |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.15 | 2019-2020 | |
| Seqirus USA INC | $58.68 | 2019-2024 | Flucelvax, Flucelvax Quadrivalent |
| Vertical Pharmaceuticals, LLC | $55.46 | 2019-2024 | Relexxii |
| Adlon Therapeutics L.P. | $42.92 | 2021 | |
| Supernus Pharmaceuticals, INC. | $40.61 | 2021 | |
| Cognoa, INC. | $26.87 | 2022 | |
| Hologic Sales and Service, LLC | $24.80 | 2024 | Aptima |
| Phadia US INC. | $22.72 | 2024 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $21.84 | 2025 | Neffy |
| Meridian Bioscience INC. | $19.86 | 2020 | |
| Almirall LLC | $19.75 | 2022 | |
| Organon LLC | $18.15 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.04 | 2023 | Crysvita |
| Aytu Biopharma, INC. | $15.38 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.